Time‐Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial Carcinoma

• Váldodahkkit: Justin J. Wilkins (Dahkki), Brigitte Brockhaus (Dahkki), Haiqing Dai (Dahkki), Yulia Vugmeyster (Dahkki), Joleen T. White (Dahkki), Satjit Brar (Dahkki), Carlo L. Bello (Dahkki), Berend Neuteboom (Dahkki), Janet R. Wade (Dahkki), Pascal Girard (Dahkki), Akash Khandelwal (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Wiley, 2019-06-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Avelumab, a human anti-programmed death ligand 1 immunoglobulin G1 antibody, has shown efficacy and manageable safety in multiple tumors. A two‐compartment population pharmacokinetic model for avelumab incorporating intrinsic and extrinsic covariates and time‐varying clearance (CL) was identified ba...